Occam Continues to Serve the Gene Therapy/Gene Editing Space, Recruiting Wes Miller as CMO of Epic Bio

Epic Bio is a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCasproteins.  The company's technology originated in the Stanford lab of scientific founder Lei Stanley Qi, a leading CRISPR pioneer and student of Jennifer Doudna.  Wes Miller joins as Epic Bio prepares to initiate a first-in-human study of its lead candidate in early 2024.  

Wes brings over two decades of combined clinical practice and biopharmaceutical industry experience to the Chief Medical Officer position.  As an associate professor of pediatrics at the University of Minnesota, Wes' research and clinical interests included using BMT and gene-modified cell therapies for patients with life-threatening and life-limiting heritable metabolic and storage diseases.  He then held roles of increasing responsibility at Sangamo Therapeutics, Astellas Gene Therapies, and, most recently, Graphite Bio.

Wes trained in pediatric hematology and oncology at Emory University and pediatric blood and marrow transplantation and cellular therapy at the University of Minnesota.  He received his M.D. from Louisiana StateUniversity and his B.S. in chemistry from Stanford University.

Occam previously worked with Dr. Qi and Horizons Ventures on the placement of Epic Bio's CEO, Amber Salzman.